Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson,Rab K. Prinjha,Antje Dittmann,George Giotopoulos,Marcus Bantscheff,Wai-In Chan,Samuel C. Robson,Chun-wa Chung,Carsten Hopf,Mikhail M. Savitski,Carola Huthmacher,Emma Gudgin,Dave Lugo,Soren Beinke,Trevor D. Chapman,Emma J. Roberts,Peter E. Soden,Kurt R. Auger,Olivier Mirguet,Konstanze Doehner,Ruud Delwel,Alan K. Burnett,Phillip Jeffrey,Gerard Drewes,Kevin Lee,Brian J. P. Huntly,Tony Kouzarides
DOI: https://doi.org/10.1038/nature10509
IF: 64.8
2011-10-01
Nature
Abstract:BET proteins as targets in mixed lineage leukaemiaRearrangements of the MLL (mixed lineage leukaemia) gene, and chimaeric MLL-fusion proteins, occur in a number of aggressive leukaemias including acute myeloid leukemia (AML). Tony Kouzarides and colleagues now find that MLL-fusion proteins are associated with BET family proteins in transcription factor complexes. GSK1210151A (I-BET151), a new small-molecule inhibitor of the interaction between BET family proteins and specific chromatin marks, is shown to have efficacy against AML cells in vitro and in mouse models, suggesting a new therapeutic strategy for AML.
multidisciplinary sciences